| Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study (NCT07509112) | Kirby Institute | 2026-09-01 |
| Oritavancin for Treatment of Serious Cardiac Infections (NCT07550595) | Kirby Institute | 2026-07-01 |
| Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases (NCT07145736) | Kirby Institute | 2025-08-04 |
| Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (NCT06317051) | Kirby Institute | 2024-12-16 |
| PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. (NCT06220370) | Kirby Institute | 2024-03-01 |
| National Prisons Hepatitis Education Project: Research Evaluation (NCT05942937) | Kirby Institute | 2023-09-04 |
| Immunosuppression and COVID-19 Boosters (NCT05415267) | Kirby Institute | 2023-07-21 |
| The National Australian HCV Point-of-Care Testing Program - Minimal Dataset (NCT05248555) | Kirby Institute | 2023-01-23 |
| Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool (NCT05144776) | Kirby Institute | 2022-11-17 |
| A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs (NCT04428346) | Kirby Institute | 2022-10-01 |
| Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs (NCT04014179) | Kirby Institute | 2022-07-27 |
| Australian Hepatitis and Risk Survey in Prisons (NCT05839522) | Kirby Institute | 2022-04-27 |
| The Australian HCV Point-of-Care Testing Program (NCT05042544) | Kirby Institute | 2022-02-23 |
| Real World Assessment of People Living With Chronic Hepatitis B in Australia (NCT04914611) | Kirby Institute | 2022-02-17 |
| Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays (NCT04289428) | Kirby Institute | 2022-01-01 |
| Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (NCT04415424) | Kirby Institute | 2021-07-08 |
| D²EFT Graphical Informed Consent (NCT04668443) | Kirby Institute | 2021-03-22 |
| Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (NCT03981211) | Kirby Institute | 2021-02-12 |
| Inflammation and Co-Infections in D²EFT (NCT04183738) | Kirby Institute | 2021-02-01 |
| COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings (NCT04371835) | Kirby Institute | 2020-08-12 |
| Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA) (NCT04354818) | Kirby Institute | 2020-05-11 |
| Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales (NCT04383652) | Kirby Institute | 2020-05-06 |
| Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (NCT03855917) | Kirby Institute | 2020-02-11 |
| Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia (NCT03709459) | Kirby Institute | 2019-12-17 |
| Body Composition Sub-study of the D2EFT Trial (NCT03675815) | Kirby Institute | 2019-12-05 |
| Prisons Evaluation of a One-stop-shop InterVentiOn (NCT04809246) | Kirby Institute | 2019-10-31 |
| Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (NCT03776760) | Kirby Institute | 2019-05-28 |
| Simplified Monitoring Myanmar SM2 Study (NCT04113629) | Kirby Institute | 2019-01-22 |
| Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings (NCT03343925) | Kirby Institute | 2018-08-17 |
| ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (NCT03685045) | Kirby Institute | 2018-05-28 |
| The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar (NCT04132479) | Kirby Institute | 2018-01-01 |
| Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) (NCT04641013) | Kirby Institute | 2017-12-05 |
| Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (NCT03017872) | Kirby Institute | 2017-11-23 |
| Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial (NCT03327155) | Kirby Institute | 2017-11-16 |